55 results about "Prostate cancer cell line" patented technology

The invention relates to an olefinated estrogen compound (I), a preparation method thereof and application thereof to the preparation of an antineoplastic drug. The invention has the beneficial effects which are mainly embodied in that (1), an olefinated estrogen drug provided by the invention is novel in structure, has favorable antineoplastic activity, and particularly has excellent inhibitory activity to the cell line MCF-7 of a mammary cancer and a cell line PC-7 of a prostatic cancer; and (2), a preparation method of the olefinated estrogen drug, which is provided by the invention, can beused for preparing and obtaining the olefinated estrogen drug in a high-yield manner by only needing one step, and has the characteristics of being simple, efficient, convenient and quick, and the like.

The invention discloses an amide compound and an application thereof in treating cancer, and belongs to the field of pharmaceutical chemistry. The invention discloses the application of amide compoundshown in formula I, or crystal form, or stereoisomer, or isotope body, or tautomer, or pharmaceutically-acceptable salt, or solvate, or pro-drug, or metabolite thereof in treating cancer. Experimental results show that the compound can inhibit the proliferation of prostate cancer cells, especially has an obvious inhibition effect on drug-resistant prostate cancer cell line (22RV1). At the same time, the compound can obviously inhibit the proliferation of multiple cancer cells. In addition, the compound has good pharmacokinetics, which has a potential therapeutic effect on cancer, especially prostate cancer, and provides a new choice for clinical screening and/or preparation of cancer drugs.

The invention belongs to the technical field of medical biology, and discloses a molecular marker-LncRNA SNHG11 for auxiliary diagnosis of prostatic cancer. The LncRNA SNHG11 is highly expressed in cancer tissues of prostatic cancer, and is lowly expressed in paracancerous normal tissues; moreover, the expression level of the LncRNA SNHG11 in a prostatic cancer cell line is obviously higher than that of a normal prostate cell line; proliferation, migration and invasion of prostatic cancer cells can be obviously inhibited by knocking down the expression level of the LncRNA SNHG11 gene. Therefore, the LncRNA SNHG11 can be used as a molecular marker for auxiliary diagnosis of the prostatic cancer; by detecting the expression level of the LncRNA SNHG11 in a sample, auxiliary diagnosis can be carried out on the prostatic cancer, and a reference basis is provided for clinical doctors to diagnose the prostatic cancer.

PVT1 exon 9 is overexpressed in aggressively tumorigenic prostate cancer cell lines and prostate tumor tissues. This exon provides a diagnostic tool for the detection and monitoring of aggressive prostate cancer. Several small interfering ribonucleic acids (siRNAs) are disclosed that are useful for treating prostate cancer.

Oligoamine compounds with anti-cancer and anti-proliferative activity are provided, as well as methods for making and using the compounds. The compounds are shown to be active against prostate cancer cell lines and against prostate cancer tumors in mice. The compounds are also useful in treatment of breast cancer and other cancers.

The invention relates to the field of medical technique research and discloses a prostatic cancer stem cell marker, application of an antibody OV6 in the preparation of a prostatic cancer stem cell marking material and a marking method. The marking method comprises the following steps: marking a prostate cancer cell line or a prostate tissue cell by virtue of a mouse-source OV6 antibody; incubating the prostate cancer cell line or the prostate tissue cell together with rat anti-mouse IgG and magnetic beads; putting the prostate cancer cell line or the prostate tissue cell on an MACS MS column,and carrying out filtration separation, so as to obtain an OV6 positive prostatic cancer cell; and finally detecting the marking efficiency of the OV6 positive prostatic cancer cell by virtue of a flow cytometry. Furthermore, enzalutamide is utilized for realizing drug stimulation so as to enhance the marking effect before the marking of the mouse-source OV6 antibody. According to the marking method, the prostatic cancer stem cell can be remarkably marked, and the OV6 positive cell has high expression dryness-related gene and high granulation rate and tumor formation rate. The marking methodhas relatively high specificity and sensitivity and important clinical values.

The invention discloses a 18beta-glycyrrhetinic acid carbamate derivative, which has a structure shown as formula (I) or (II) in the specification. The compound provided by the invention has a brand new structure, and has significant inhibitory effect on lung cancer, liver cancer, colon cancer, breast cancer and prostate cancer cell lines. And the antitumor activity of parts of the compounds is close to crizotinib.

Accordingly, embodiments herein disclose a compound and method of small molecule inhibitors or ligands for diagnosis and treatment of cancers such as prostate, brain, breast, etc., and neurodegenerative diseases. A new class of PSMA inhibitors called as aminoacetamide, 1, has been designed by extensive in silico studies. A simple, mild and high yielding synthetic methodology is developed for 1 and shown to have high affinity for PSMA protein. Fluorescent conjugates 22 and 25 derived from 1 show selective uptake in prostate cancer cell lines and can be used for surgical removal of tumors during intra-operative surgery. Conjugates 31 and 34 for tagging 99mTc radioisotope were synthesized. Macrocyclic chelating cores such as DOTA, NOTA or prosthetic groups can be introduced to tag radionuclides 68Ga, 64Cu, 18F and 177Lu for diagnosis and treatment of PCa, incurable mCRPC and neurodegenerative diseases such as ALS, schizophrenia and neuropathic pain that over-express PSMA protein.

The present invention relates to a prostate cancer cell line CNCM deposit number I-4126, the use thereof for preparing resistant prostate cancer cell lines, the resistant prostate cancer cell lines, and the use of these prostate cancer cell lines for screening compounds of interest.

An object is to find a target molecule effective for cancer treatments and the like and to provide an antibody capable of specifically binding to the molecule, an anticancer agent comprising the antibody as an active ingredient, and so forth. Hence, prostate cancer cell lines (LNCaP-CR cells and LNCaP cells) were compared by SST-REX, and CXADR was identified as a molecule involved in tumor formation and so on. Then, a monoclonal antibody against CXADR was prepared, and the anti-cancer activity, ADCC activity, CDC activity, and so forth were examined. The result revealed that an antibody capable of binding to an epitope present at positions 181 to 230 of a CXADR protein derived from human exhibited an anti-cancer activity against prostate cancer cells, pancreatic cancer cells, and colorectal cancer cells. Further, it was also revealed that the antibody had an ADCC activity and a CDC activity. Moreover, the structures of light chain and heavy chain variable regions of the antibody were successfully determined.